Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype

BACKGROUND: Glioblastoma (GBM) is the most common and most aggressive primary malignant brain tumor. Standard-of-care treatment involves maximal surgical resection of the tumor followed by radiation and chemotherapy (temozolomide [TMZ]). The 5-year survival rate of patients with GBM is <10%, a co...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Teng, Jian, Hejazi, Seyedali, Hiddingh, Lotte, Carvalho, Litia, de Gooijer, Mark C, Wakimoto, Hiroaki, Barazas, Marco, Tannous, Marie, Chi, Andrew S, Noske, David P, Wesseling, Pieter, Wurdinger, Thomas, Batchelor, Tracy T, Tannous, Bakhos A
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2018
Soggetti:
Basic and Translational Investigations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5892145/
https://ncbi.nlm.nih.gov/pubmed/29099956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox198
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi